Understanding AIM for Investors

NexImmune's Artificial Immune Modulation (AIM) platform is the scientific foundation behind the company's therapeutic programs. For investors new to the story, this page summarizes how the technology works, which product formats the company has pursued, and where to find supporting disclosures on this site.

AIM uses nanoparticles to present immune signals to T cells in a controlled way. The particles are designed to mimic key functions of dendritic cells, the cells that normally instruct T cells which targets to attack. By programming those signals, NexImmune can aim to expand T cells against selected antigens or modulate responses in autoimmune settings.

Two Product Formats

AIM ACT (adoptive cellular therapy): Patient or donor T cells are expanded outside the body using AIM nanoparticles, then returned as a cell therapy. NexImmune's NEXI-001 and NEXI-002 programs followed this model in hematologic cancers, including relapsed acute myeloid leukemia after transplant and relapsed or refractory multiple myeloma.

AIM INJ (direct injection): Nanoparticles are injected to act on T cells inside the body without a full cell manufacturing cycle. Public updates from 2023 onward described a strategic emphasis on AIM INJ development in oncology and autoimmune disease after the company aligned its workforce to extend runway.

Clinical and Business Context

Phase 1/2 trials for NEXI-001 and NEXI-002 generated data the company has discussed at medical meetings and in press releases. Investors reviewing those studies should read the original release and any related 8-K or 10-Q filings on the Financials and Filings page rather than relying on summaries alone.

In August 2023, NexImmune announced a workforce reduction to prioritize AIM INJ while retaining core capabilities. In February 2024, the company reported a registered direct offering priced at-the-market under Nasdaq rules. Both events are documented in the press release archive.

Questions Investors Often Ask

How is AIM different from other T cell therapies? Many approved or experimental T cell therapies use genetic engineering (for example CAR-T). AIM focuses on selecting and expanding T cells using synthetic immune signals delivered by nanoparticles, without necessarily altering the cell's genome.

Where can I track pipeline updates? Program status, scientific publications, and corporate pipeline descriptions are maintained on neximmune.com. Material events that could affect the investment case are typically filed as press releases and SEC documents linked from this investor site.

Who should I contact with IR questions? Use the form and contact details on the Investor Contact page. To receive automated notices when the company posts news or filings, sign up under Email Alerts.

Return to the investor relations home page for stock quotes, events, and the latest releases.